Mind Medicine (MindMed) Inc. Completes Nasdaq Up-Listing

April 28, 2021

Mind Medicine (MindMed) Inc., a leading psychedelic medicine biotech company, has completed its up-listing to The Nasdaq Capital Market, where its subordinate voting shares will begin trading under the symbol “MNMD”. MindMed will retain its listing on the Neo Exchange Inc. under the symbol “MMED”. The Nasdaq listing is anticipated to increase MindMed’s visibility in the marketplace, improve liquidity, broaden and diversify MindMed’s shareholder base, and ultimately enhance long-term shareholder value. Upon the commencement of trading on Nasdaq, the market cap of Mindmed exceeded US $1.0 Billion.

Wildeboer Dellelce LLP acted for MindMed in its Nasdaq up-listing with a team that included Perry Dellelce, Peter Volk, Rebecca Cochrane and Katie Drury (corporate/securities).